<DOC>
	<DOCNO>NCT01806857</DOCNO>
	<brief_summary>The purpose study determine whether Nuedexta effective treatment symptom ( impaired speech , swallow , saliva control ) associate Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Clinical Trial Nuedexta Subjects With ALS</brief_title>
	<detailed_description>Muscle weakness , cardinal feature ALS , lead progressive loss motor function affect limb , tongue , respiratory pharyngeal muscle . Symptomatic treatment placement feed tube , compensate inability swallow . Riluzole , approve treatment ALS , may slow disease progression treatment curative none improve function . Unexpectedly , Nuedexta® , approve treatment labile emotionality occur association ALS neurological disorder , observe improve bulbar function , primarily speech swallowing , number neurological disorder , include ALS . The basis conjectural likely due direct effect drug motor neuron part brain control speech swallowing . The part brain appear modulate expression emotion interestingly site action drug site implicate juvenile form ALS . This multicenter , randomize double-blind , placebo control , cross study evaluate palliative effect Nuedexta® bulbar dysfunction . It expect approximately 60 ALS patient 7 clinical center US enrol .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<criteria>ALS diagnose possible , laboratorysupported probable , probable , definite define revise El Escorial criterion Age 18 year old Exhibits bulbar dysfunction manifest dysarthria and/or dysphagia , accord PI judgment , exhibit score 55 CNSBulbar Function Scale Capable provide informed consent follow trial procedure Geographic accessibility site Women must able become pregnant duration study must willing two contraceptive therapy Slow vital capacity ( SVC ) measure ≥50 % predict gender , height , age screen visit Must able swallow capsule throughout course study , accord PI judgment Subjects must take riluzole least 30 day 50mg BID dose riluzole least 30 day prior randomization ( subject never take riluzole permit study ) Subjects take antisialorrhea medication ( ) must stable dose least 30 day prior randomization ( antisialorrhea naïve subject permit study ) Must able safely swallow least 30 milliliter ( mLs ) water water swallow test Prior use Nuedexta® Current use dextromethorphan , quinidine , quinine , mefloquine opioids History quinidine , quinine , mefloquineinduced thrombocytopenia , hepatitis , hypersensitivity reaction History know sensitivity intolerability dextromethorphan Use mono amine oxidase inhibitor ( MAOI ) within 14 day stop MAOI Prolonged QT interval , congenital long QT syndrome , history suggestive torsades de pointes , heart failure Complete atrioventricular ( AV ) block without implant pacemaker , subject high risk complete AV block Concomitant use drug prolong QT interval metabolize cytochrome P 2D6 ( CYP2D6 ) ( i.e. , thioridazine pimozide ) Exposure experimental agent ( offlabel use investigational ) within 30 day prior Baseline Visit Invasive ventilator dependence , tracheostomy Any history either substance abuse within past year , unstable psychiatric disease , cognitive impairment , dementia , accord PI judgment Placement and/or usage feed tube Pregnant woman woman currently breastfeed Unable turn diaphragm pace device swallow test Salivatory Botox within 90 day ( 3 month ) screen Salivatory radiation within 180 day ( 6 month ) screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Amyotrophic lateral sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Nuedexta</keyword>
	<keyword>Bulbar function</keyword>
	<keyword>motor neuron</keyword>
</DOC>